164 related articles for article (PubMed ID: 19140232)
1. Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C.
Gelu-Simeon M; Burlaud A; Young J; Pelletier G; Buffet C
World J Gastroenterol; 2009 Jan; 15(3):328-33. PubMed ID: 19140232
[TBL] [Abstract][Full Text] [Related]
2. Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C.
Moncoucy X; Leymarie F; Delemer B; Lévy S; Bernard-Chabert B; Bouché O; Jolly D; Diebold MD; Cadiot G; Thiéfin G
Gastroenterol Clin Biol; 2005 Apr; 29(4):339-45. PubMed ID: 15864192
[TBL] [Abstract][Full Text] [Related]
3. Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study.
Kabbaj N; Guedira MM; El Atmani H; El Alaoui M; Mohammadi M; Benabed K; Lachkar H; Benaïssa A
Ann Endocrinol (Paris); 2006 Sep; 67(4):343-7. PubMed ID: 17072240
[TBL] [Abstract][Full Text] [Related]
4. [Natural history of dysthyroidism during interferon treatment of chronic hepatitis C].
Mekkakia-Benhabib C; Marcellin P; Colas-Linhart N; Castel-Nau C; Buyck D; Erlinger S; Bok B
Ann Endocrinol (Paris); 1996; 57(5):419-27. PubMed ID: 8991106
[TBL] [Abstract][Full Text] [Related]
5. Phenotypes of interferon-α-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex.
Mammen JS; Ghazarian SR; Pulkstenis E; Subramanian GM; Rosen A; Ladenson PW
J Clin Endocrinol Metab; 2012 Sep; 97(9):3270-6. PubMed ID: 22689690
[TBL] [Abstract][Full Text] [Related]
6. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
[TBL] [Abstract][Full Text] [Related]
7. Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C.
Hwang Y; Kim W; Kwon SY; Yu HM; Kim JH; Choe WH
Korean J Intern Med; 2015 Nov; 30(6):792-800. PubMed ID: 26552454
[TBL] [Abstract][Full Text] [Related]
8. Interaction of interferon alpha therapy with thyroid function tests in the management of hepatitis C: a case report.
Gill G; Bajwa H; Strouhal P; Buch HN
J Med Case Rep; 2016 Sep; 10(1):253. PubMed ID: 27632981
[TBL] [Abstract][Full Text] [Related]
9. [Dysthyroidism in patients treated with interferon alpha].
Chédin P; Chanson P; Duranteau L; Guillausseau PJ; Lubetzki J
Presse Med; 1994 Nov; 23(36):1659-63. PubMed ID: 7899293
[TBL] [Abstract][Full Text] [Related]
10. Thyroid dysfunction and long-term outcome during and after interferon-alpha therapy in patients with chronic hepatitis C.
Vasiliadis T; Anagnostis P; Nalmpantidis G; Soufleris K; Patsiaoura K; Grammatikos N; Orfanou-Koumerkeridou E; Kargiotis K; Slavakis A; Deliyiannidis A; Eugenidis N
Ann Acad Med Singap; 2011 Sep; 40(9):394-400. PubMed ID: 22065032
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha induced transient thyroid dysfunction in hepatitis C.
Fernández-Díez S; Rodríguez-Agulló JL; Cascudo Rielo MJ; Navarro Angulo N; Díaz-Rubio M
Rev Esp Enferm Dig; 2002 Mar; 94(3):159-63. PubMed ID: 12185880
[TBL] [Abstract][Full Text] [Related]
12. [Analysis of thyroid dysfunction and influencing factors in chronic hepatitis C patients treated with peg-IFNa-2a and ribavirin].
Huang YX; Chen XY; Ma LN; Yin JM; Ren S; Guo DD; Zheng YH
Zhonghua Gan Zang Bing Za Zhi; 2012 Mar; 20(3):216-20. PubMed ID: 22475143
[TBL] [Abstract][Full Text] [Related]
13. The addition of ribavirin to interferon-alpha therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism.
Carella C; Mazziotti G; Morisco F; Rotondi M; Cioffi M; Tuccillo C; Sorvillo F; Caporaso N; Amato G
Eur J Endocrinol; 2002 Jun; 146(6):743-9. PubMed ID: 12039693
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology, risk factors and prognosis of Interferon alpha induced thyroid disorders. A Prospective Clinical Study.
Obołończyk Ł; Siekierska-Hellmann M; Wiśniewski P; Lewczuk A; Berendt-Obołończyk M; Lakomy A; Michalska Z; Radowska D; Moszkowska G; Bianek-Bodzak A; Sworczak K
Postepy Hig Med Dosw (Online); 2017 Sep; 71(0):842-849. PubMed ID: 29039351
[TBL] [Abstract][Full Text] [Related]
15. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
[TBL] [Abstract][Full Text] [Related]
16. The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy.
Huang JF; Chuang WL; Dai CY; Chen SC; Lin ZY; Lee LP; Lee PL; Wang LY; Hsieh MY; Chang WY; Yu ML
J Viral Hepat; 2006 Jun; 13(6):396-401. PubMed ID: 16842442
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan.
Chang YK; Tseng YT; Chen KH; Chen KT
BMC Endocr Disord; 2019 Apr; 19(1):36. PubMed ID: 30953492
[TBL] [Abstract][Full Text] [Related]
18. Serum CXCL10 levels and occurrence of thyroid dysfunction in patients treated with interferon-alpha therapy for hepatitis C virus-related hepatitis.
Rotondi M; Minelli R; Magri F; Leporati P; Romagnani P; Baroni MC; Delsignore R; Serio M; Chiovato L
Eur J Endocrinol; 2007 Apr; 156(4):409-14. PubMed ID: 17389454
[TBL] [Abstract][Full Text] [Related]
19. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy.
Marazuela M; García-Buey L; González-Fernández B; García-Monzón C; Arranz A; Borque MJ; Moreno-Otero R
Clin Endocrinol (Oxf); 1996 Jun; 44(6):635-42. PubMed ID: 8759175
[TBL] [Abstract][Full Text] [Related]
20. [Hepatitis C virus infection and thyroid diseases].
Broussolle C; Steineur MP; Bailly F; Zoulim F; Trépo C
Rev Med Interne; 1999 Sep; 20(9):766-73. PubMed ID: 10522298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
